Trial Information

Summary: Newly Diagnosed CML Study - CAMN107A2303

Novartis Oncology is conducting this clinical research study is to determine if two doses of the investigational drug nilotinib are safe and effective when compared to imatinib mesylate (GleevecŪ) in newly diagnosed patients with Philadelphia chromosome positive (Ph+) Chronic Myelogenous Leukemia (CML). An "investigational drug" is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).

The duration of the study is approximately 5 years until participants experience disease progression or develop an intolerance of the study treatment.
For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 22, 2008 at 2:59:36 PM